Section 4 of 6
Clinical evidence
587 evidence topics · 82 sources
Study summaries
ABTECT-1
Objective
Primary objectives for the FDA and for the EMA in the protocol
Place of the trial in the phase 3 development plan
Main objective in the EU Clinical Trials Information System record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2022-11-16” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-06-24” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-06-25” (opens the source at this quote in a new tab)
“First Posted 2022-08-18” (opens the source at this quote in a new tab)
“Results First Posted 2026-09-10” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-10” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Planned number of sites and potential countries in the protocol
Sites and countries of the two induction trials stated by the company
Start of the phase 3 trials and first U.S. enrollment
EU member states and trial dates in the EU Clinical Trials Information System record
Study design
Periods, randomization ratio, and planned arm sizes in the protocol
Randomization stratification factors
Endoscopy, central reading, and electronic diaries
Independent central review of video-recorded endoscopies stated by the company
Entry into the maintenance trial after Week 8
Rationale for the doses and the 8-week treatment duration in the protocol
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
Definition of inadequate response to JAK inhibitors in the protocol
Eligibility summarized in the late-breaking abstract
“The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Arms and administration in the ClinicalTrials.gov record
Capsule strengths and dosing instructions in the protocol
Background ulcerative colitis therapy allowed during the trial
Doses and route stated by the company
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Primary endpoint and its definition in the ClinicalTrials.gov record
FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint
Reason the physician global assessment is excluded from the modified Mayo Score
FDA recommendations on entry criteria and central reading of endoscopy
Company statement that the endpoint and entry criteria follow FDA guidance
Co-primary endpoints for the EMA: endoscopic improvement and symptomatic remission
Secondary endpoint definitions in the ClinicalTrials.gov record
Patient-reported and other secondary endpoints in the protocol
Status of symptomatic remission under each regulatory protocol in the late-breaking abstract
“Symptomatic remission was an “other secondary” endpoint, not multiplicity controlled, for the FDA protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Participants analyzed by arm in the posted results
| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
|---|---|---|---|---|
| Started | “318” | “161” | “160” | Not reported |
| Baseline (Full Analysis Set) | “318” | “160” | “158” | “636” |
| Primary and secondary endpoints (Full Analysis Set) | “318” | “160” | “158” | Not reported |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” | Not reported |
Participants randomized and treated in the late-breaking abstract
Participants randomized across both induction trials stated by the company
Description of analysis sets
Full Analysis Set and participants randomized but not dosed
Analysis sets in the statistical analysis plan
Primary analysis method and testing sequence in the protocol
Handling of intercurrent events and missing data in the statistical analysis plan
Testing hierarchy and pooled analysis in the late-breaking abstract
“Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NRI is used for subjects with missing outcome at week 8 and subjects reporting any IE prior to week 8. % Difference is for Obe minus placebo and is based on estimated common risk difference using the Mantel‐Haenszel weights adjusting for the randomization stratification factors: inadequate response to advanced therapies (yes/no), baseline oral corticosteroids usage (yes/no), and region (Japan/rest of world) [ABTECT‐2 only].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for pooled analysis, all p ‐values are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Participant flow by arm in the posted results
| Disposition | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| Started | “318” | “161” | “160” |
| Completed | “291” | “155” | “143” |
| Not completed | “27” | “6” | “17” |
| Adverse event | “18” | “0” | “6” |
| Lost to follow-up | “1” | “1” | “1” |
| Never dosed | “0” | “1” | “1” |
| Non-compliance with study drug | “2” | “0” | “0” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “0” | “1” |
| Withdrawal by subject | “4” | “4” | “7” |
Pooled ABTECT-1 and ABTECT-2: study discontinuation and reasons
| Disposition | Obefazimod 50 mg | Obefazimod 25 mg | Placebo |
|---|---|---|---|
| Participants who discontinued the study, n (%) | “54 (8.5)” | “23 (7.2)” | “31 (9.7)” |
| Adverse event, n (% of discontinuations) | “31 (57.4)” | “8 (34.8)” | “14 (45.2)” |
| Withdrawal by subject | “13 (24.1)” | “10 (43.5)” | “10 (32.3)” |
| Lack of efficacy | “2 (3.7)” | “2 (8.7)” | “1 (3.2)” |
| Lost to follow-up | “4 (7.4)” | “1 (4.3)” | “1 (3.2)” |
Pooled ABTECT-1 and ABTECT-2: entry into the maintenance trial
Baseline characteristics
Baseline characteristics by arm in the posted results
| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=160) | Placebo (n=158) | Total (n=636) |
|---|---|---|---|---|
| Age, years, mean (SD) | “42.7(14.3)” | “41.5(13.54)” | “43.1(13.59)” | “42.5(13.93)” |
| Age 65 years or older, participants | “25” | “12” | “11” | “48” |
| Female, participants | “129” | “56” | “66” | “251” |
| Male, participants | “189” | “104” | “92” | “385” |
| Asian, participants | “87” | “34” | “45” | “166” |
| Black or African American, participants | “5” | “3” | “2” | “10” |
| White, participants | “219” | “114” | “106” | “439” |
| Weight, kg, mean (SD) | “72.41(18.581)” | “72.58(17.269)” | “71.28(16.392)” | “72.17(17.713)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.98(7.348)” | “7.8(7.151)” | “7.51(7.761)” | “7.82(7.395)” |
| At least one prior advanced therapy inadequate response, participants | “149” | “70” | “69” | “288” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “22” | “15” | “15” | “52” |
| Modified Mayo Score, mean (SD) | “6.9(1.06)” | “6.8(1.04)” | “6.9(1.04)” | “6.9(1.05)” |
| Mayo endoscopic subscore 2, participants | “128” | “69” | “64” | “261” |
| Mayo endoscopic subscore 3, participants | “190” | “91” | “94” | “375” |
| Fecal calprotectin, µg/g, mean (SD) | “3768.46(6219.12)” | “2533.58(3761.06)” | “5390.53(9479.94)” | “3828.77(6729.81)” |
Proportion with prior advanced therapy inadequate response in the late-breaking abstracts
“In both trials, baseline demographics and disease characteristics were similar between groups; 45.3% and 49.3% of pts had inadequate response to one or more advanced therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: endoscopic severity and prior JAK inhibitor failure
Pooled ABTECT-1 and ABTECT-2: baseline disease extent
Pooled ABTECT-1 and ABTECT-2: baseline disease duration
Pooled ABTECT-1 and ABTECT-2: treatment exposure
| Exposure | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
|---|---|---|---|
| Duration of exposure, days, mean (SD) | “58.8 (12.62)” | “59.5 (11.14)” | “58.7 (11.14)” |
| Duration of exposure, days, median [min, max] | “60.0 [1, 106]” | “61.0 [4, 96]” | “61.0 [5, 102]” |
Efficacy results
Primary and key secondary endpoints at Week 8
Participants meeting each endpoint at Week 8 in the posted results
Primary endpoint result stated by the company
Pooled ABTECT-1 and ABTECT-2: primary and secondary endpoints at Week 8
“In a pooled analysis, both Obe‐50 and Obe‐25 met all primary and secondary endpoints with nominal significance ( p < 0.0001) (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for pooled analysis, all p ‐values are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: early symptomatic improvement from Week 1
Pooled presentation of both trials: miR-124 expression and serum IL-17A and IL-6 at Week 8
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Pooled ABTECT-1 and ABTECT-2: subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Pooled ABTECT-1 and ABTECT-2: clinical response by prior JAK inhibitor failure and number of failed advanced therapies (nominal p-values)
“In the AT‐IR‐No subgroup, Obe‐50 and Obe‐25 performed similarly in the pooled analysis across efficacy measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: definition of inadequate response to advanced therapies in the subgroup analysis
Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease extent (post hoc, nominal p-values)
Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease duration (post hoc, nominal p-values)
Health-related quality of life and patient-reported outcomes
Pooled ABTECT-1 and ABTECT-2: bowel urgency, nocturnal bowel movements, and fatigue at Week 8
Pooled ABTECT-1 and ABTECT-2: disease-specific and overall quality of life (IBDQ and EQ-5D-5L)
Pooled ABTECT-1 and ABTECT-2: work productivity and activity impairment (WPAI:UC)
Safety results
Treatment-emergent adverse events at Week 8 reported by the company
| Event, n (%) | Placebo (N=158) | Obefazimod 25 mg (N=160) | Obefazimod 50 mg (N=318) |
|---|---|---|---|
| Any TEAE | “84 (53.2%)” | “75 (46.9%)” | “189 (59.4%)” |
| TEAE leading to study drug discontinuation | “6 (3.8%)” | “0 (0.0%)” | “17 (5.3%)” |
| Serious TEAE | “3 (1.9%)” | “1 (0.6%)” | “14 (4.4%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “1 (0.3%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “1 (0.6%)” | “1 (0.6%)” | “2 (0.6%)” |
Serious adverse events, all-cause mortality, and adverse event time frame in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Any serious adverse event | “14/318 (4.40%)” | “1/160 (0.63%)” | “3/158 (1.90%)” |
| Myocardial infarction | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis acute | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Colitis ulcerative | “3/318 (0.94%)” | “0/160 (0.00%)” | “2/158 (1.27%)” |
| Pneumonia | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Appendicitis | “0/318 (0.00%)” | “1/160 (0.63%)” | “0/158 (0.00%)” |
| Prostate cancer stage I | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
Non-serious adverse events at a 5% reporting threshold in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| Any non-serious adverse event at 5% threshold | “90/318 (28.30%)” | “34/160 (21.25%)” | “28/158 (17.72%)” |
| Headache | “66/318 (20.75%)” | “25/160 (15.63%)” | “9/158 (5.70%)” |
| Nausea | “18/318 (5.66%)” | “5/160 (3.13%)” | “1/158 (0.63%)” |
| Anaemia | “10/318 (3.14%)” | “6/160 (3.75%)” | “9/158 (5.70%)” |
| Colitis ulcerative | “6/318 (1.89%)” | “0/160 (0.00%)” | “8/158 (5.06%)” |
| Arthralgia | “8/318 (2.52%)” | “1/160 (0.63%)” | “8/158 (5.06%)” |
Adverse events in the late-breaking abstract
“Proportions of pts who reported at least one TEAE in ABTECT‐1 were 59.4%, 46.9%, and 53.2% for Obe‐50, Obe‐25, and PBO, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent TEAE was headache (Obe‐50: 20.8%–25.8%; Obe‐25: 14.5%–15.6%; PBO: 5.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The headaches were mild, transient, short in duration and not a barrier to treat as evidenced by a low discontinuation rate of 0%–1.6%. No signal was observed for serious, severe, or opportunistic infections or malignancies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled ABTECT-1 and ABTECT-2: integrated summary of treatment-emergent adverse events
| Event, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
|---|---|---|---|
| Any TEAE | “383 (60.2)” | “156 (48.9)” | “161 (50.8)” |
| TEAE related to study drug | “226 (35.5)” | “86 (27)” | “55 (17.4)” |
| TEAE leading to study discontinuation | “30 (4.7)” | “6 (1.9)” | “13 (4.1)” |
| Serious TEAE | “20 (3.1)” | “7 (2.2)” | “10 (3.2)” |
| Malignancies | “1 (0.2)” | “0” | “0” |
| Serious, severe, or opportunistic infections | “4 (0.6)” | “1 (0.3)” | “1 (0.3)” |
| Headache | “148 (23.3)” | “48 (15.0)” | “18 (5.7)” |
| Nausea | “46 (7.2)” | “16 (5.0)” | “4 (1.3)” |
| Abdominal pain | “24 (3.8)” | “2 (0.6)” | “2 (0.6)” |
| Lipase increased | “27 (4.2)” | “9 (2.8)” | “7 (2.2)” |
| Time to onset of first headache, days, median | “1.0” | “1.0” | “7.0” |
Pooled ABTECT-1 and ABTECT-2: adverse events leading to study drug discontinuation
Pooled ABTECT-1 and ABTECT-2: infection-related adverse events
| Infection, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
|---|---|---|---|
| Nasopharyngitis | “14 (2.2)” | “9 (2.8)” | “10 (3.2)” |
| Upper respiratory tract infection | “7 (1.1)” | “3 (0.9)” | “6 (1.9)” |
| COVID-19 | “6 (0.9)” | “4 (1.3)” | “1 (0.3)” |
| Influenza | “6 (0.9)” | “3 (0.9)” | “1 (0.3)” |
| Urinary tract infection | “5 (0.8)” | “2 (0.6)” | “0” |
| Pneumonia | “4 (0.6)” | “0” | “1 (0.3)” |
Pooled ABTECT-1 and ABTECT-2: integrated safety abstract
Pooled ABTECT-1 and ABTECT-2: headache and nausea rates reported at UEG Week 2025
Headache: most frequent adverse event in the ABTECT induction trials
Integrated safety of the ABTECT induction trials
Adverse events of special interest in the phase 3 protocol
Hepatic enzymes: protocol summary of clinical data
Study limitations
Summary: study limitations
- Duration and comparator: ABTECT-1 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks. It has no active comparator, and the durability of response is assessed only in the separate ABTECT Maintenance trial, which enrolled Week 8 responders from both induction trials.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), congress abstracts and posters, and company press releases and filings. The counts differ between sources: the registry lists 639 participants enrolled, the participant flow starts with 318, 161, and 160 by arm, and the Full Analysis Set holds 636, because one participant randomized to 25 mg and two randomized to placebo were never dosed.
- Placebo group and background therapy: randomization was 2:1:1, so the placebo arm holds 158 participants, of whom 4 (2.5%) reached clinical remission at Week 8. Stable oral 5-ASA and oral corticosteroids were allowed, and the protocol states that such background therapy “may be partially effective at controlling UC symptoms”.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Isolated proctitis, primary sclerosing cholangitis, creatinine clearance below 60 mL/min, QT prolongation, and HIV infection were exclusions. Of the 636 participants analyzed, 288 (45.3%) had a prior inadequate response to an advanced therapy and 52 had a prior inadequate response to a JAK inhibitor; 48 were 65 years or older, 10 were Black or African American, and 166 were Asian. The registry lists 264 locations.
- Endpoints for two regulators: the FDA primary endpoint is clinical remission by the modified Mayo Score; for the EMA, endoscopic improvement and symptomatic remission are co-primary endpoints, and symptomatic remission was not multiplicity controlled under the FDA testing scheme. The Form 20-F describes the primary endpoint as requiring a stool frequency subscore “not greater than baseline”, a condition the registry and protocol definitions do not state.
- Statistical reporting: the posted protocol omits the assumed treatment difference, power, and placebo remission rate behind the sample size of 612 (“difference of at least” is followed by no value). The pooled ABTECT-1 and ABTECT-2 analyses, including the pooled subgroup analyses, report nominal p-values, and the analysis by disease extent is post hoc. Subgroups are small: among participants with prior advanced therapy inadequate response, 6 of 70 (8.6%) receiving 25 mg and 1 of 69 (1.4%) receiving placebo reached clinical remission (p=0.0556).
- Safety reporting: serious adverse events occurred in 14 of 318 participants (4.40%) receiving 50 mg, 1 of 160 (0.63%) receiving 25 mg, and 3 of 158 (1.90%) receiving placebo; events in the 50 mg arm included one myocardial infarction, one acute pancreatitis, one pancreatitis, and one stage I prostate cancer. Figures differ between company sources: the rate of discontinuation for headache is given as “0%–1.6%” in the UEG Week 2025 abstract and “0-1.1%” in the integrated safety abstract, and pooled headache with 50 mg as 24.1% in a press release and 23.3% (148 of 636) in the integrated safety poster.
ABTECT-2
Objective
Primary objectives for the FDA and for the EMA in the protocol
Place of the trial in the phase 3 development plan
Main objective in the EU Clinical Trials Information System record
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-01-25” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-06-24” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-07-15” (opens the source at this quote in a new tab)
“First Posted 2022-08-18” (opens the source at this quote in a new tab)
“Results First Posted 2026-09-10” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-10” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
Planned number of sites and potential countries in the protocol
EU member states and trial dates in the EU Clinical Trials Information System record
Sites and countries of the two induction trials stated by the company
Study design
Periods, randomization ratio, and planned arm sizes in the protocol
Randomization stratification factors, including region
Endoscopy, central reading, and electronic diaries
Rationale for the 8-week treatment duration in the protocol
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record
Minimum age by region in the protocol
Age range in the EU Clinical Trials Information System record
Eligibility summarized in the late-breaking abstract
“The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Arms and administration in the ClinicalTrials.gov record
Capsule strengths and dosing instructions in the protocol
Background ulcerative colitis therapy allowed during the trial
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Primary endpoint and its definition in the ClinicalTrials.gov record
FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint
Co-primary endpoints for the EMA and key secondary endpoints for the FDA
Secondary endpoint definitions in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size in the protocol
Actual enrollment in the ClinicalTrials.gov record
Participants analyzed by arm in the posted results
| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
|---|---|---|---|---|
| Started | “318” | “159” | “159” | Not reported |
| Baseline | “318” | “159” | “159” | “636” |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” | Not reported |
Participants randomized and treated in the late-breaking abstract
Description of analysis sets
Analysis population in the posted results
Analysis sets in the statistical analysis plan
Primary analysis method, region factor, and testing sequence in the protocol
Handling of intercurrent events and missing data in the statistical analysis plan
Consequence of the 25 mg primary endpoint result for the testing hierarchy
“Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics
Baseline characteristics by arm in the posted results
| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=159) | Placebo (n=159) | Total (n=636) |
|---|---|---|---|---|
| Age, years, mean (SD) | “41.4(13.64)” | “41.3(12.83)” | “41.6(14.68)” | “41.4(13.69)” |
| Age 65 years or older, participants | “19” | “6” | “16” | “41” |
| Female, participants | “138” | “60” | “58” | “256” |
| Male, participants | “180” | “99” | “101” | “380” |
| Asian, participants | “66” | “29” | “39” | “134” |
| Black or African American, participants | “6” | “3” | “4” | “13” |
| White, participants | “231” | “116” | “108” | “455” |
| Weight, kg, mean (SD) | “71.75(17.101)” | “73.37(16.050)” | “73.91(17.387)” | “72.69(16.919)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.74(7.193)” | “7.92(6.769)” | “7.75(6.503)” | “7.79(6.911)” |
| At least one prior advanced therapy inadequate response, participants | “159” | “76” | “79” | “314” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “33” | “19” | “20” | “72” |
| Modified Mayo Score, mean (SD) | “6.9(1.11)” | “7.0(1.04)” | “6.8(0.98)” | “6.9(1.06)” |
| Mayo endoscopic subscore 2, participants | “130” | “56” | “64” | “250” |
| Mayo endoscopic subscore 3, participants | “188” | “103” | “95” | “386” |
| Fecal calprotectin, µg/g, mean (SD) | “3759.05(7548.48)” | “4121.86(7081.92)” | “4499.81(8074.99)” | “4038.06(7569.95)” |
Disease severity of the 25 mg group compared with ABTECT-1 stated by the company
Proportion with prior advanced therapy inadequate response in the late-breaking abstract
“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Primary and key secondary endpoints at Week 8
“25 mg did not meet the primary endpoint at week 8 in ABTECT‐2 in the FDA testing protocol, therefore p ‐values for key secondary endpoints for the 25 mg arm in ABTECT‐2 are nominal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants meeting each endpoint at Week 8 in the posted results
Primary endpoint result for the 25 mg dose stated by the company
Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events at Week 8 reported by the company
| Event, n (%) | Placebo (N=159) | Obefazimod 25 mg (N=159) | Obefazimod 50 mg (N=318) |
|---|---|---|---|
| Any TEAE | “77 (48.4%)” | “81 (50.9%)” | “194 (61.0%)” |
| TEAE leading to study drug discontinuation | “9 (5.7%)” | “8 (5.0%)” | “15 (4.7%)” |
| Serious TEAE | “7 (4.4%)” | “6 (3.8%)” | “6 (1.9%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “0 (0.0%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “0 (0.0%)” | “0 (0.0%)” | “2 (0.6%)” |
Serious adverse events, all-cause mortality, and adverse event time frame in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/318 (0.00%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Any serious adverse event | “6/318 (1.89%)” | “6/159 (3.77%)” | “7/159 (4.40%)” |
| Colitis ulcerative | “2/318 (0.63%)” | “2/159 (1.26%)” | “3/159 (1.89%)” |
| Pancreatitis acute | “0/318 (0.00%)” | “1/159 (0.63%)” | “1/159 (0.63%)” |
| Pneumonia | “1/318 (0.31%)” | “0/159 (0.00%)” | “0/159 (0.00%)” |
| Uveitis | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Lipase increased | “0/318 (0.00%)” | “1/159 (0.63%)” | “0/159 (0.00%)” |
| Acute coronary syndrome | “0/318 (0.00%)” | “0/159 (0.00%)” | “1/159 (0.63%)” |
Non-serious adverse events at a 5% reporting threshold in the posted results
| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
|---|---|---|---|
| Any non-serious adverse event at 5% threshold | “115/318 (36.16%)” | “40/159 (25.16%)” | “32/159 (20.13%)” |
| Headache | “82/318 (25.79%)” | “23/159 (14.47%)” | “9/159 (5.66%)” |
| Nausea | “29/318 (9.12%)” | “11/159 (6.92%)” | “3/159 (1.89%)” |
| Lipase increased | “19/318 (5.97%)” | “2/159 (1.26%)” | “4/159 (2.52%)” |
| N-terminal prohormone brain natriuretic peptide increased | “7/318 (2.20%)” | “3/159 (1.89%)” | “11/159 (6.92%)” |
| Anaemia | “12/318 (3.77%)” | “6/159 (3.77%)” | “11/159 (6.92%)” |
Adverse events in the late-breaking abstract
“For ABTECT2, TEAEs occurred in 61.0%, 50.9%, and 48.4% for Obe‐50, Obe‐25, and PBO, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall rate of serious adverse events and treatment emergent adverse events (TEAEs) leading to study drug discontinuation for pts treated with Obe were similar to PBO.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: study limitations
- Duration and comparator: ABTECT-2 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks, and has no active comparator. Durability is assessed only in the separate ABTECT Maintenance trial. The pooled ABTECT-1 and ABTECT-2 analyses, including all patient-reported outcome results, are recorded under ABTECT-1; no patient-reported outcome result specific to ABTECT-2 was identified.
- Primary endpoint by dose: the 50 mg dose met the primary endpoint (clinical remission 19.8% against 6.3% with placebo; difference 13.4%, p=0.0001). The 25 mg dose did not (11.3% against 6.3%; difference 5.1%, p=0.1034), so under the hierarchical testing scheme the p-values for its key secondary endpoints are nominal. The company states that a “slightly more severe and refractory population” was randomized to 25 mg in ABTECT-2 than in ABTECT-1; in the posted baseline data, 76 of 159 participants receiving 25 mg had a prior advanced therapy inadequate response and 103 had a Mayo endoscopic subscore of 3.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), a congress abstract, and company press releases and filings. The posted results do not specify the analysis population for baseline characteristics or outcome measures.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, Israel, Serbia, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Of 636 participants, 314 (49.4%) had a prior advanced therapy inadequate response and 72 had a prior inadequate response to a JAK inhibitor; 41 were 65 years or older and 13 were Black or African American. Randomization was also stratified by region (Japan or rest of world), and the registry lists 262 locations. The protocol excludes the region factor from the primary analysis model “for consistency with ABX464-105”.
- Background therapy: stable oral 5-ASA and oral corticosteroids were allowed in all arms, and the protocol states that such therapy “may be partially effective at controlling UC symptoms”.
- Subgroups: subgroup results by prior advanced therapy inadequate response come from small groups. Among participants with a prior inadequate response, clinical remission occurred in 4 of 76 (5.3%) receiving 25 mg and 4 of 79 (5.1%) receiving placebo (p=0.8529), and in 20 of 159 (12.6%) receiving 50 mg (p=0.0652).
- Safety reporting: serious adverse events occurred in 6 of 318 participants (1.89%) receiving 50 mg, 6 of 159 (3.77%) receiving 25 mg, and 7 of 159 (4.40%) receiving placebo. Non-serious lipase increase was reported in 19 of 318 (5.97%) receiving 50 mg and 4 of 159 (2.52%) receiving placebo, and serious acute pancreatitis in 1 participant receiving 25 mg and 1 receiving placebo.
ABTECT maintenance
Objective
Objective of the subgroup presentation by prior advanced therapy response
Purpose and primary objectives of Part 1 and Part 2 in the ClinicalTrials.gov record
Main objectives of Part 1, Part 2, and the long-term extension in the EU register
Location and study date
Study dates and number of locations in the ClinicalTrials.gov record
“Study Start (Actual) 2023-01-16” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-04-28” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2030-05” (opens the source at this quote in a new tab)
“This study has 413 locations” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Countries, sites, and trial duration in the EU register
Phase 3 program: 36 countries and over 600 sites, first U.S. participant in October 2022
Part 2 topline results announced June 29, 2026
Presentation at UEG Week 2026 in Barcelona
Study design
Official title and design details in the ClinicalTrials.gov record
Two treatment phases: a 44-week maintenance phase (Part 1 and Part 2) and a 4-year long-term extension
Randomization by induction treatment and response status
Part 1: re-randomization of obefazimod induction responders to 25 mg, 50 mg, or placebo
Responder definition, stratification factors, and placebo induction responders
Part 2: induction non-responders and Part 1 relapsers
Central endoscopy reading and primary endpoint at the end of the 44-week maintenance trial (52 weeks in total)
Eligibility criteria
Inclusion criteria for the maintenance phase in the ClinicalTrials.gov record
Exclusion criteria for the maintenance phase in the ClinicalTrials.gov record
Minimum age of 16 years, or 18 years in the EU/EEA, Israel, Serbia, and Ukraine
Long-term extension entry criteria
Treatment
Long-term extension: continued allocated treatment for up to 4 years
Investigational products: 25 mg and 50 mg hard capsules and matching placebo
Dose escalation to open-label 50 mg after relapse in Part 1
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
FDA recommendation: proportion in clinical remission by the modified Mayo Score as the primary endpoint
FDA recommendation: induction followed by randomized withdrawal maintenance with evaluation at about 52 weeks
FDA recommendation: remission in participants entering maintenance in remission to show durability
Company definition of the primary endpoint and its basis in FDA guidance
Primary endpoint and key secondary endpoints as presented at UEG Week 2026
Corticosteroid-free clinical remission: registered in the subpopulation receiving corticosteroids at maintenance entry
EU register: endoscopic improvement and symptomatic remission as Part 1 primary endpoints, clinical remission as a secondary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Planned participants in the EU register
Induction responders entering Part 1: 678 of 1,275
Part 1 analysis population: 580 obefazimod induction responders
| Group | Participants |
|---|---|
| Obefazimod induction responders | “Obefazimod Induction Responders (n=580)” |
| Placebo | “Placebo (n=192)” |
| Obefazimod 25 mg | “25 mg (n=193)” |
| Obefazimod 50 mg | “50 mg (n=195)” |
Part 2 induction non-responders and Part 1 relapsers analyzed for efficacy
Part 2 safety population: 186 participants on 25 mg and 447 on 50 mg
Description of analysis sets
Treatment differences: Mantel-Haenszel common risk difference adjusted for the stratification factors
Multiplicity control of the key secondary endpoints
Subgroup analyses by prior advanced therapy response: unadjusted differences and nominal p-values
Part 2 and integrated safety analyses: post-hoc, exposure-adjusted
Results
Participant disposition
Week 44 completion without relapse or treatment switch, by group
| Measure | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
|---|---|---|---|
| Study participants | “192” | “193” | “195” |
| Week 44 completion rate | “66 (34.3%)” | “152 (78.8%)” | “160 (82.1%)” |
Completion of the 44-week maintenance phase at the December 2025 data safety monitoring board review
Completion of the 44-week treatment period at the March 2026 data safety monitoring board review
Baseline characteristics
Part 1 baseline characteristics by group
| Characteristic | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
|---|---|---|---|
| Study participants | “192” | “193” | “195” |
| Age (years), mean (SD) | “41.3 (13.4)” | “43.0 (13.7)” | “42.3 (14.4)” |
| Induction baseline modified Mayo Score, mean (SD) | “6.9 (1.1)” | “6.7 (1.1)” | “6.9 (1.2)” |
| Duration of disease (years), mean (SD) | “8.1 (7.6)” | “8.1 (7.4)” | “7.8 (6.9)” |
| Induction baseline fecal calprotectin (mg/g), median | “1,202” | “1,585” | “1,568” |
| Corticosteroid use at maintenance baseline | “35.9%” | “41.5%” | “40.5%” |
| Clinical remission at maintenance baseline | “27.1%” | “37.8%” | “32.3%” |
| Prior advanced therapy failure | “37.5%” | “39.4%” | “46.2%” |
Higher proportion with prior advanced therapy failure in the 50 mg group
Definition of prior inadequate response to advanced therapy
Efficacy results
Part 1 primary and key secondary endpoints at Week 44
| Endpoint at Week 44 | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) | Difference, 25 mg | Difference, 50 mg | P value (both doses) |
|---|---|---|---|---|---|---|
| Clinical remission, n (%) | “20 (10.4%)” | “98 (50.8%)” | “100 (51.3%)” | “∆39.3%” | “∆40.3%” | “<0.0001” |
| Endoscopic improvement, n (%) | “24 (12.5%)” | “106 (54.9%)” | “125 (64.1%)” | “∆42.5%” | “∆51.0%” | “<0.0001” |
| Endoscopic remission, n (%) | “19 (9.9%)” | “80 (41.5%)” | “93 (47.7%)” | “∆31.4%” | “∆37.8%” | “<0.0001” |
| HEMI, n (%) | “20 (10.4%)” | “97 (50.3%)” | “112 (57.4%)” | “∆39.4%” | “∆46.5%” | “<0.0001” |
| Corticosteroid-free clinical remission, n (%) | “19 (9.9%)” | “87 (45.1%)” | “93 (47.7%)” | “∆35.1%” | “∆38.0%” | “<0.0001” |
| Sustained clinical remission, n/N (%) | “8/51 (15.7%)” | “49/73 (67.1%)” | “40/61 (65.6%)” | “∆52.8%” | “∆49.1%” | “<0.0001” |
Placebo clinical remission rate of 10.4% as characterized by the company
Week 52 reporting at UEG Week 2026: the same results expressed as 52 weeks of treatment overall
Other secondary endpoints at Week 52: clinical response and symptomatic remission
| Endpoint at Week 52 | Placebo, n/N | Placebo, % | Obefazimod 25 mg, n/N | Obefazimod 25 mg, % | Obefazimod 50 mg, n/N | Obefazimod 50 mg, % | Difference, 25 mg | Difference, 50 mg |
|---|---|---|---|---|---|---|---|---|
| Clinical response | “51/192” | “26.6%” | “135/193” | “69.9%” | “147/195” | “75.4%” | “∆ 42.8%” | “∆ 49.7%” |
| Symptomatic remission | “44/192” | “22.9%” | “129/193” | “66.8%” | “128/195” | “65.6%” | “∆ 42.5%” | “∆ 41.0%” |
Clinical endpoints at Week 52 by prior inadequate response to advanced therapy
| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
|---|---|---|---|---|---|---|---|
| No prior AT-IR: clinical remission | “15/120” | “72/117” | “62/105” | “∆ 48%” | “p<0.0001” | “∆ 45%” | “p<0.0001” |
| No prior AT-IR: corticosteroid-free clinical remission | “15/120” | “64/117” | “59/105” | “∆ 42%” | “p<0.0001” | “∆ 43%” | “p<0.0001” |
| No prior AT-IR: sustained clinical remission | “5/38” | “42/58” | “27/38” | “∆ 62%” | “p<0.0001” | “∆ 55%” | “p=0.0003” |
| Prior AT-IR: clinical remission | “5/72” | “26/76” | “38/90” | “∆ 28%” | “p<0.0001” | “∆ 33%” | “p<0.0001” |
| Prior AT-IR: corticosteroid-free clinical remission | “4/72” | “23/76” | “34/90” | “∆ 26%” | “p=0.0001” | “∆ 31%” | “p<0.0001” |
| Prior AT-IR: sustained clinical remission | “3/13” | “7/15” | “13/23” | “∆ 24%” | “p=0.6873” | “∆ 30%” | “p=0.0915” |
Endoscopic and histologic-endoscopic endpoints at Week 52 by prior inadequate response to advanced therapy
| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N |
|---|---|---|---|
| No prior AT-IR: endoscopic improvement | “18/120” | “77/117” | “77/105” |
| No prior AT-IR: endoscopic remission | “15/120” | “62/117” | “58/105” |
| No prior AT-IR: HEMI | “15/120” | “71/117” | “68/105” |
| Prior AT-IR: endoscopic improvement | “6/72” | “29/76” | “48/90” |
| Prior AT-IR: endoscopic remission | “4/72” | “18/76” | “35/90” |
| Prior AT-IR: HEMI | “5/72” | “26/76” | “44/90” |
Clinical remission at Week 52 by number of prior advanced therapies with inadequate response and after JAK inhibitor failure
| Subgroup | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
|---|---|---|---|---|---|---|---|
| No prior AT-IR | “15/120” | “72/117” | “62/105” | “∆ 49%” | “p<0.0001” | “∆ 47%” | “p<0.0001” |
| One prior AT-IR | “4/27” | “12/31” | “17/41” | “∆ 24%” | “p=0.2785” | “∆ 27%” | “p=0.0584” |
| Two prior AT-IR | “0/24” | “7/22” | “8/19” | “∆ 32%” | “p=0.0215” | “∆ 42%” | “p=0.0014” |
| Three prior AT-IR | “1/12” | “4/12” | “10/21” | “∆ 25%” | “p=0.0771” | “∆ 39%” | “p=0.0968” |
| Four or more prior AT-IR | “0/9” | “3/11” | “3/9” | “∆ 27%” | “NC” | “∆ 33%” | “p=0.1967” |
| Prior JAK inhibitor inadequate response | “0/16” | “4/14” | “5/15” | “∆ 29%” | “p=0.0190” | “∆ 33%” | “p=0.0375” |
Conclusions of the subgroup presentation
Part 2: Part 1 relapsers re-treated with obefazimod 50 mg, exploratory endpoints at Week 44
Health-related quality of life and patient-reported outcomes
IBDQ response: long-term extension endpoint in the EU register, no results reported
Safety results
Part 1 treatment-emergent adverse events over 44 weeks
| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
|---|---|---|---|
| Any TEAE | “96 (50.0%)” | “112 (58.0%)” | “140 (71.8%)” |
| TEAE leading to study drug discontinuation | “13 (6.8%)” | “5 (2.6%)” | “9 (4.6%)” |
| Serious TEAE | “8 (4.2%)” | “5 (2.6%)” | “11 (5.6%)” |
| Death | “0” | “0” | “0” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “2 (1.0%)” | “2 (1.0%)” | “1 (0.5%)” |
| Acute pancreatitis | “0” | “0” | “0” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” | “0” |
| Malignancy other than NMSC: prostate cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: breast cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: colonic dysplasia | “0” | “0” | “1 (0.5%)” |
| NMSC: basal cell carcinoma | “1 (0.5%)” | “0” | “2 (1.1%)” |
| NMSC: squamous cell carcinoma | “0” | “1 (0.5%)” | “2 (1.1%)” |
Part 1 malignancies and non-melanoma skin cancers as described by the company
Part 1 related serious adverse events, pregnancies, and colonic dysplasia as presented at UEG Week 2026
| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
|---|---|---|---|
| Patients with any related serious TEAE | “1 (0.5%)” | “0” | “0” |
| Pregnancy | “0” | “0” | “2 (1.1%)” |
Part 2 treatment-emergent adverse events in induction non-responders and Part 1 relapsers
| Event, n (%) | Obefazimod 25 mg (N=186) | Obefazimod 50 mg (N=447) |
|---|---|---|
| Any TEAE | “132 (71.0%)” | “307 (68.7%)” |
| TEAE leading to study drug discontinuation | “21 (11.3%)” | “27 (6.0%)” |
| Serious TEAE | “16 (8.6%)” | “23 (5.1%)” |
| Death, not treatment related | “1 (0.5%)” | “0” |
| Pregnancy | “1 (0.5%)” | “1 (0.2%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “5 (2.7%)” | “5 (1.1%)” |
| Malignancies excluding NMSC | “0” | “2 (0.4%)” |
| NMSC | “2 (1.1%)” | “2 (0.4%)” |
| Acute pancreatitis | “1 (0.5%)” | “1 (0.2%)” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” |
Part 2 death, infections, and malignancies: footnotes to the safety table
Part 2 malignancies and non-melanoma skin cancers: case characteristics and investigator assessment
| Case | Dose | Exposure to obefazimod | Age | Thiopurine history | Medical history of cancer or skin cancer | Investigator assessment |
|---|---|---|---|---|---|---|
| Myeloproliferative neoplasm | “50 mg” | “7.4 months” | “40+” | “No” | “No” | “Determined not related to study drug by investigator” |
| Prostate cancer | “50 mg” | “3.4 months” | “55+” | “Yes azathioprine” | “No” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “50 mg” | “10.4 months” | “40+” | “Yes azathioprine” | “No” | “Determined probably related to study drug by investigator” |
| Squamous cell carcinoma | “50 mg” | “4.6 months” | “55+” | “Yes azathioprine” | “Yes” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “25 mg” | “8.1 months” | “50+” | “Yes azathioprine” | “No” | “Determined unlikely related to study drug by investigator” |
| Squamous cell carcinoma | “25 mg” | “8.3 months” | “75+” | “No” | “Yes” | “Determined probably related to study drug by investigator” |
Part 2 malignancies and non-melanoma skin cancers as described by the company
Exposure-adjusted incidence of malignancies excluding NMSC (post-hoc), with the company's expected background range
| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
|---|---|---|---|---|---|
| Integrated UC program (phase 2 and phase 3) | “0.00” | “0.00” | “0.64” | “0.35” | “0.30 – 0.70” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.00” | “0.00” | “0.91” | “0.56” | “0.30 – 0.70” |
| Part 2 only | “-” | “0.00” | “0.69” | “0.48” | “0.30 – 0.70” |
Exposure-adjusted incidence of non-melanoma skin cancer (post-hoc), with the company's expected background range
| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
|---|---|---|---|---|---|
| Integrated UC program (phase 2 and phase 3) | “0.46” | “0.53” | “0.64” | “0.59” | “0.70 – 1.40” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.68” | “1.09” | “1.37” | “1.26” | “0.70 – 1.40” |
| Part 2 only | “-” | “1.52” | “0.69” | “0.95” | “0.70 – 1.40” |
Company interpretation of the exposure-adjusted malignancy analyses
Interim data safety monitoring board reviews in December 2025 and March 2026
Study limitations
Summary
As of November 2026, the results of ABTECT Maintenance come only from company press releases of June 1 and June 29, 2026, a prospectus supplement, and two slide presentations at UEG Week 2026. No peer-reviewed publication exists, the ClinicalTrials.gov record shows “No Results Posted”, and the EU register states that the trial has not ended; no protocol or statistical analysis plan for this trial is posted on ClinicalTrials.gov. The long-term extension continues to an estimated study completion in May 2030.
Part 1 is a randomized withdrawal design. Its 580 analyzed participants (192 placebo, 193 obefazimod 25 mg, 195 obefazimod 50 mg) had all responded to 8 weeks of obefazimod induction, so the placebo group measures withdrawal of obefazimod after an initial response; participants without an induction response are reported separately in Part 2. Of the 678 induction responders who entered Part 1, placebo induction responders were kept on blinded placebo and are outside the 580-participant comparison. Completion of Week 44 without relapse or treatment switch was 66 of 192 (34.3%) with placebo, against 152 of 193 (78.8%) and 160 of 195 (82.1%) with obefazimod 25 mg and 50 mg, so most placebo participants left the randomized treatment before Week 44; the handling of these participants in the efficacy analysis has not been published.
The timepoint is reported as Week 44 in the press releases and registry and as “Week 52” in the UEG Week slides, which count the 8-week induction. The registries differ: ClinicalTrials.gov names clinical remission at Week 44 as the Part 1 primary endpoint, while the EU register states the Part 1 objective as comparing obefazimod with placebo on “endoscopic improvement and symptomatic remission” and lists clinical remission at Week 44 among the Part 1 endpoints. Symptomatic remission (66.8% and 65.6% with obefazimod against 22.9% with placebo) is reported only in the slides, and its printed definition reads “RBS=0, SFS <1”. Corticosteroid-free clinical remission is registered in the subpopulation receiving corticosteroids at maintenance entry, while the reported counts (19 of 192, 87 of 193, and 93 of 195) use all randomized participants as the denominator.
Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups. Placebo-adjusted differences were numerically smaller in participants with prior inadequate response to advanced therapy (clinical remission differences of 28% and 33%) than in those without (48% and 45%). The subgroup analyses by number of prior advanced therapies and after JAK inhibitor failure involved 9 to 41 participants per group, and their differences are unadjusted with nominal p-values that the presenters describe as “descriptive rather than confirmatory”; the sustained clinical remission subgroup with prior advanced therapy failure included 13, 15, and 23 participants.
Part 2 efficacy results come from groups without a placebo comparator: induction non-responders who continued obefazimod (81 on 25 mg and 148 on 50 mg) and Part 1 relapsers re-treated with open-label 50 mg (109 previously on placebo and 33 previously on 25 mg). The company labels these results exploratory and the integrated safety analyses post-hoc.
Malignancy findings rest on small numbers of events. In Part 1, the 50 mg group had one prostate cancer, one breast cancer, and one colonic dysplasia, listed by the release under malignancies other than NMSC, and four NMSC (two basal cell and two squamous cell carcinomas), against one NMSC with placebo and one with 25 mg; no malignancy other than NMSC occurred with placebo or 25 mg. Part 2 added two malignancies excluding NMSC (a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers re-treated with 50 mg) and four NMSC, two of which the investigators judged probably related to study drug. In the phase 3 maintenance dataset, the exposure-adjusted incidence of NMSC was 1.37 per 100 patient-years with 50 mg and 0.68 with placebo, and of malignancies excluding NMSC 0.91 with 50 mg and 0.00 with placebo. The company's comparison of these rates with a “UC background reference range” is post-hoc and compares the trial's rates with an external reference range from published studies. Part 2 also reported one death from suspected pulmonary embolism, assessed as unrelated, and one case of acute pancreatitis in each dose group, an event with no cases in Part 1.
ABX464-103
Objective
Purpose stated in the ClinicalTrials.gov record
Primary objective in the protocol: dose selection
Selected secondary objectives in the protocol
Rationale for the study in the protocol: phase 2a results
Location and study date
Registered locations
Centres, countries, and enrollment period in the published report
“In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between Aug 13, 2019, and April 16, 2021, 254 patients were randomly allocated to ABX464 100 mg (n=64), ABX464 50 mg (n=63), ABX464 25 mg (n=63), or placebo (n=64).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Trial registration printed in the published abstract
Study design
Randomised, double-blind, placebo-controlled, four-group design
“In this phase 2b, double-blind, randomised, placebo-controlled induction trial, patients were recruited from 95 centres (hospitals and health-care centres) in 16 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Enrolled patients were randomly assigned (1:1:1:1) via an interactive voice and web response system to receive once daily oral ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, or matched placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Randomisation was stratified according to study site (US vs non-US) and to whether the patient had previous exposure to second-line treatment with biologics or JAK inhibitors.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Model description | “Randomized, double blind, placebo controlled, parallel groups” |
| Masking | “Quadruple” |
| Phase | “Phase 2” |
| Enrollment (actual) | “355” |
Treatment groups and duration in the ClinicalTrials.gov record
Limits on previous advanced therapy exposure, central endoscopy reading, and e-diaries
Endoscopy schedule and exit for disease progression
Duration of participation and roll-over to the open-label extension
Dose limiting toxicity rule and Data Safety Monitoring Board
Eligibility criteria
Key eligibility criteria in the published report
“Eligible patients were aged 18-75 years, with a diagnosis of moderate-to-severe, active ulcerative colitis and a modified Mayo Score (MMS) of 5 points or higher, and a documented non-response or intolerance to previous treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria in the ClinicalTrials.gov record: disease activity and previous treatment
Inclusion criteria in the ClinicalTrials.gov record: background therapy and washout
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and capsule regimens in the ClinicalTrials.gov record
Formulation and administration in the protocol
Allowed concomitant medications in the protocol
Prohibited medications in the protocol, including CYP1A2 substrates
Study outcomes
Rationale for using change in modified mayo score as the primary endpoint
Registered primary outcome measure and the modified Mayo score
Modified Mayo score compared with the total Mayo score in the protocol
Secondary endpoint definitions in the protocol: clinical remission, clinical response, endoscopic improvement, and mucosal healing
Central reading of endoscopy in the registered secondary outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size assumptions in the protocol
Participants consented, randomized, treated, and analyzed in the posted results
Exclusions from the full analysis set in the published report
Description of analysis sets
Full analysis set and safety population in the published report
“The primary efficacy analysis was done in the full analysis set (FAS), defined as all randomly assigned patients who received at least one dose of study treatment and had baseline data for at least one efficacy variable, and was analysed according to the principles of intention-to-treat.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Safety analyses included patients who had been randomly assigned and who received at least one dose of study treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets in the statistical analysis plan
Primary analysis model and fixed testing sequence in the protocol
Results
Participant disposition
Discontinuations and exclusions in the posted results
Baseline characteristics
Baseline characteristics in the posted results
| Characteristic | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo | Total |
|---|---|---|---|---|---|
| Participants | “64” | “63” | “61” | “64” | “252” |
| Age, years, mean (SD) | “42.2(12.34)” | “40.2(13.94)” | “41.5(14.16)” | “41.1(14.43)” | “41.2(13.67)” |
| Female | “23” | “36” | “21” | “24” | “104” |
| Male | “41” | “27” | “40” | “40” | “148” |
| Baseline MMS 5 to 6 | “17” | “16” | “17” | “21” | “71” |
| Baseline MMS 7 to 9 | “47” | “47” | “44” | “42” | “180” |
Race and ethnicity not collected
Disease severity and refractoriness of the induction population
“Of the 252 patients treated in the induction trial, baseline disease activity was severe (MMS of 7–9) in 71.4% of patients, and more than 45% of patients were refractory to 2 or more advanced targeted therapies at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Induction results reported in the maintenance study publication
“More than 45% had failed at least 2 prior advanced targeted therapies (biologics or JAK inhibitors). Obefazimod (25, 50, or 100 mg) significantly reduced the modified Mayo score (MMS) at week 8, meeting the primary endpoint. Improvements were seen in both naïve and bio/JAK refractory patients in key secondary outcomes, including clinical remission, response, endoscopic, and histologic–endoscopic mucosal improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint: change from baseline in modified Mayo score at week 8
“In the FAS at week 8, the least squares mean (LSM) change from baseline in MMS was -2·9 (95% CI -3·4 to -2·5) for the ABX464 100 mg group, -3·2 (-3·7 to -2·7) for the ABX464 50 mg group, -3·1 (-3·6 to -2·6) for the ABX464 25 mg group, and -1·9 (-2·4 to -1·5) for placebo group; the magnitude of the difference in MMS from baseline was significantly greater in all three ABX464 groups compared with placebo (p=0·0039 for ABX464 100 mg vs placebo, p=0·0003 for ABX464 50 mg vs placebo, and p=0·0010 for ABX464 25 mg vs placebo).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Primary outcome in the posted results: least squares mean change in MMS at week 8
| Group | Least squares mean | 95% confidence interval |
|---|---|---|
| ABX464 100 mg | “-2.9” | “(-3.4 to -2.5)” |
| ABX464 50 mg | “-3.2” | “(-3.7 to -2.7)” |
| ABX464 25 mg | “-3.1” | “(-3.6 to -2.6)” |
| Matching placebo | “-1.9” | “(-2.4 to -1.5)” |
Secondary outcomes at week 8 in the posted results: number of participants
| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
|---|---|---|---|---|
| Clinical remission per MMS (64, 63, 61, 64) | “16” | “11” | “16” | “8” |
| Clinical response (64, 63, 61, 64) | “32” | “37” | “38” | “22” |
| Endoscopic improvement (54, 53, 58, 59) | “24” | “21” | “20” | “8” |
| Endoscopic remission (54, 53, 58, 59) | “2” | “5” | “4” | “5” |
| Mucosal healing (64, 63, 61, 64) | “0” | “1” | “0” | “2” |
Secondary outcomes at week 16 in the posted results: number of participants
| Outcome (participants analyzed per group) | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
|---|---|---|---|---|
| Clinical remission per MMS (31, 30, 37, 46) | “7” | “6” | “9” | “6” |
| Clinical response (31, 30, 37, 46) | “19” | “20” | “25” | “20” |
| Endoscopic improvement (32, 31, 38, 46) | “11” | “12” | “11” | “9” |
| Endoscopic remission (32, 31, 38, 46) | “1” | “1” | “2” | “3” |
Analysis population for the week 16 outcomes
Health-related quality of life and patient-reported outcomes
IBDQ planned as a secondary endpoint in the protocol
Stool frequency and rectal bleeding recorded in an electronic diary
Safety results
Headache and serious adverse events in the published report
“The most frequently reported adverse event was headache, which was reported for 27 (42%) of 64 patients in the ABX464 100 mg group, 19 (30%) of 63 in the 50 mg group, 13 (21%) of 62 in the 25 mg group, and five (8%) of 64 in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Severe (grade 3) headache was reported for three (5%) patients in the ABX464 group 100 mg group, two (3%) in the ABX464 50 mg group, one (2%) in the ABX464 25 mg group, and none in the placebo group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The only serious adverse event reported for two or more patients in any group was ulcerative colitis (one in each of the ABX464 100 mg and 50 mg groups, and three [5%] in the placebo group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events in the posted results: participants affected / at risk (%)
| Event | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching placebo |
|---|---|---|---|---|
| All-cause mortality | “0/64 (0.00%)” | “0/63 (0.00%)” | “0/62 (0.00%)” | “0/64 (0.00%)” |
| Serious adverse events, total | “4/64 (6.25%)” | “4/63 (6.35%)” | “1/62 (1.61%)” | “4/64 (6.25%)” |
| Other adverse events, total | “45/64 (70.31%)” | “38/63 (60.32%)” | “33/62 (53.23%)” | “30/64 (46.88%)” |
| Headache | “27/64 (42.19%)” | “19/63 (30.16%)” | “13/62 (20.97%)” | “5/64 (7.81%)” |
| Nausea | “9/64 (14.06%)” | “4/63 (6.35%)” | “5/62 (8.06%)” | “4/64 (6.25%)” |
| Vomiting | “5/64 (7.81%)” | “2/63 (3.17%)” | “1/62 (1.61%)” | “1/64 (1.56%)” |
| Abdominal pain upper | “4/64 (6.25%)” | “3/63 (4.76%)” | “3/62 (4.84%)” | “0/64 (0.00%)” |
Adverse event collection period in the posted results
Study limitations
Summary
ABX464-103 was a phase 2b, randomized, double-blind, placebo-controlled dose-ranging induction trial with 4 parallel groups; 254 participants were randomized and 252 were included in the full analysis set. The primary endpoint was the change from baseline in modified Mayo score at week 8, and the protocol also defined clinical remission, clinical response, and endoscopic improvement as outcomes. The posted results report the primary outcome for 58, 54, 59, and 60 participants in the 100 mg, 50 mg, 25 mg, and placebo groups, against full analysis set sizes of 64, 63, 61, and 64. The protocol scheduled week 16 endoscopy only for participants without endoscopic improvement at week 8, and the week 16 outcomes were analyzed in participants “with data available for baseline and the respective visit”. The protocol limited participants with previous exposure to biologics or JAK inhibitors to 60%, those with previous vedolizumab to 20%, and those with previous JAK inhibitors to 10%. Of 252 participants, 2 were enrolled in the United States, and race and ethnicity were not collected. The protocol planned IBDQ assessment at Week 8 and Week 16, and no IBDQ results were located in the PubMed abstract or the posted results. Headache was reported in 27 of 64, 19 of 63, 13 of 62, and 5 of 64 participants in the 100 mg, 50 mg, 25 mg, and placebo groups. The PubMed abstract gives NCT04023396, the record of the open-label maintenance study, as the trial registration.
Limitations and caveats field in the posted results
ABX464-104
Objective
Purpose stated in the ClinicalTrials.gov record
Selected secondary objectives in the protocol, including cardiac function
Location and study date
Study dates in the ClinicalTrials.gov record
“Study Start (Actual) 2020-01-13” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2023-02-23” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2023-02-23” (opens the source at this quote in a new tab)
“Results First Posted 2025-04-27” (opens the source at this quote in a new tab)
Registered locations
Centers and countries in the published report
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “217” |
Open-label design described in the ClinicalTrials.gov record
Entry regardless of induction response, continuation to week 96, and visit schedule
“Patients who had completed the induction study phase and who were willing to continue treatment could enter the OLM and receive treatment with obefazimod 50 mg od, regardless of the patient’s clinical response or randomized treatment (placebo or obefazimod 25, 50, or 100 mg od) during induction (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After week 48, patients who had shown clinical response (defined as a decrease in MMS ≥2 points and ≥30% from baseline (induction), plus a decrease in rectal bleeding subscore [RBS] ≥1 or an absolute RBS ≤1) were eligible for continued participation in the extension for a total period of 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From day 1 onwards, patients were seen at the investigational site every 4 weeks up to week 48, then at weeks 60, 72, 84, and 96; flexible sigmoidoscopy with rectal and/or sigmoidal biopsies was performed at weeks 48 and 96 (both central and blinded reading of endoscopies were assessed).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety follow-up, exit for disease progression, and roll-over to ABX464-108 in the protocol
Data and Safety Monitoring Board and Independent Cardiovascular Safety Committee
Echocardiography added after enrollment was complete
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Criteria for a second 48 weeks of treatment
Exclusion criteria in the ClinicalTrials.gov record
Induction population described in the published report
Treatment
Intervention in the ClinicalTrials.gov record
Administration in the protocol
Allowed and prohibited concomitant medications and corticosteroid tapering
“Allowed concomitant medications were continued from the baseline of the induction trial. These included corticosteroids (CS; ≤20 mg per day of prednisone or prednisone equivalent, ≤5 mg per day of beclomethasone dipropionate, or ≤9 mg per day budesonide MMX), oral 5-ASA, immunosuppressants such as azathioprine and 6-mercaptopurine, and antidiarrheals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of biologics (eg, TNF-α inhibitors, vedolizumab, ustekinumab), JAK inhibitors, cyclosporin, and tacrolimus was prohibited during the study. At the start of the OLM study, CS-tapering was recommended in all patients but was not mandatory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using clinical remission by modified mayo score as the primary endpoint
Registered primary outcome measure
Primary endpoint and remission definition in the protocol
Efficacy endpoints and definitions in the published report
“Endpoints included rate of clinical remission (defined as stool frequency subscore [SFS] ≤1 and rectal bleeding = 0 and endoscopic score of 0 or 1), rate of clinical response (defined as a decrease from baseline in MMS ≥2 points and ≥30% from baseline, plus a decrease in RBS ≥1 or an absolute RBS ≤1), rate of endoscopic improvement (endoscopic subscore ≤1), rate of endoscopic remission (endoscopic subscore = 0), change from baseline of OLM study by visit up to week 96 for stool frequency, and fecal calprotectin (FCP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CS-free status, defined as the cessation of CS for at least 12 weeks prior to each assessment time point in this analysis, was evaluated for efficacy outcomes at weeks 48 and 96 within the subgroup of patients receiving concomitant CS at the induction baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid-free clinical remission defined in the protocol
Registered secondary outcome: clinical response definition
Endoscopic improvement and fecal calprotectin as treatment targets
“Endoscopically determined improvement in mucosal appearance has been associated with more favorable long-term outcomes in patients with UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“FCP levels below 150 µg/g typically indicate remission with a high degree of accuracy according to Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE-II) recommendations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
No sample size calculation in the protocol
Participants enrolled and analyzed in the published report
“Of the 222 eligible patients who completed the induction trial, 217 (97.7%) were enrolled in the OLM study (Figure S1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis set for efficacy was the full analysis set (FAS, N = 217), and analysis of safety parameters was carried out using the safety analysis set (SAF, N = 217).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Full analysis set, safety analysis set, baseline, and nonresponder imputation in the published report
“The FAS included all patients who received at least 1 dose of obefazimod 50 mg and had a baseline of OLM data for at least 1 efficacy variable; the SAF included all patients who received at least 1 dose of obefazimod 50 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline of OLM was defined as the last non-missing measurement after induction (week 8 or 16) taken prior to the first dose of obefazimod 50 mg of the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportions of patients in clinical remission, clinical response, with endoscopic improvement, or endoscopic remission were summarized descriptively using nonresponder imputation (NRI) analysis at weeks 48 and 96 (patients with missing data were imputed as nonresponders).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets in the protocol
Two baselines and missing data rules in the statistical analysis plan
Descriptive statistics and interim analysis at week 48
Results
Participant disposition
Discontinuations by year in the published report
“Of 222 eligible patients, 217 were enrolled and 164 (75.6%) completed week 96 of the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty of 217 (13.8%) discontinued prior to week 48, 6 patients did not meet eligibility criteria for the second year of treatment (did not achieve clinical response at week 48 or were unwilling to continue) and 17/181 (9.4%) patients discontinued between weeks 48 and 96. All discontinuations were considered as treatment failures for the NRI analysis of efficacy at weeks 48 and 96.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enrollment and completion in the Form 20-F
Baseline characteristics
Demographic and baseline characteristics in the published report
Baseline characteristics described in the text of the published report
“At baseline of OLM, the mean age was 42.1 years; 61.3% of patients were men; 162 patients were randomized to 1–3 doses of obefazimod and 55 patients to placebo in the induction trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At baseline of OLM, 98 patients (45.2%) had prior inadequate response to biologics or JAK inhibitors (70 of these 98 (71.4%) patients had inadequate response to ≥2 biologics or JAK inhibitors), 119/217 patients (54.8%) were naive to biologics or JAK inhibitors and 120/217 patients (55.3%) were using concomitant corticosteroids (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Clinical and endoscopic outcomes at weeks 48 and 96, all participants (nonresponder imputation)
“Among the 217 patients who enrolled in the OLM study and received 50 mg od oral dosing with obefazimod, 177/217 (81.6%) and 158/217 (72.8%) achieved clinical response at weeks 48 and 96, respectively, and 119/217 (54.8%) and 114/217 (52.5%) patients achieved clinical remission at weeks 48 and 96, respectively. Furthermore, 133/217 (61.3%) and 128/217 (59.0%) patients had endoscopic improvement at weeks 48 and 96, while 72/217 (33.2%) and 78/217 (35.9%) patients attained endoscopic remission at weeks 48 and 96, respectively (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary outcome in the posted results: clinical remission at week 48 (of 217)
| Outcome | Participants |
|---|---|
| Clinical remission at week 48 | “119” |
Week 48 and week 96 outcomes reported in the Form 20-F
Outcomes by clinical response at week 8 of induction
“Among the 124 patients with clinical response at week 8 of the induction trial, 82/124 (66.1%) and 74/124 (59.7%) achieved clinical remission at weeks 48 and 96, respectively (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 93 patients that did not achieve clinical response at week 8 of the induction trial, 37/93 (39.8%) and 40/93 (43.0%) achieved clinical remission at weeks 48 and 96, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes by induction treatment: obefazimod or placebo
“Overall, 162 patients treated with obefazimod during induction entered the OLM. Among this subgroup, 103/162 (63.6%) achieved clinical response at W8 of the induction trial, while 59/162 (36.4%) did not.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, clinical remission was achieved by 69/103 (67.0%) and 65/103 (63.1%) among W8 clinical responders at W48 and W96, respectively, compared to 20/59 (33.9%) and 24/59 (40.7%) among W8 nonresponders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 55 patients receiving placebo during induction and entering the OLM, 21/55 (38.2%) achieved clinical response at W8 of the induction trial, while 34/55 (61.8%) did not. Clinical remission was achieved by 13/21 (61.9%) and 9/21 (42.9%) of W8 clinical responders at W48 and W96, respectively, compared to 17/34 (50.0%) and 16/34 (47.1%) of nonresponders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes by previous biologic or JAK inhibitor exposure
“Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 119 patients naïve to biologics or JAK inhibitors at the induction study baseline, 103/119 (86.6%) and 92/119 (77.3%) achieved a clinical response at weeks 48 and 96. In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid-free outcomes in participants receiving corticosteroids at induction baseline
“Among the 115 patients enrolled in the OLM who received concomitant CS at induction baseline, 64/115 (55.7%) were in clinical remission rates at week 48 and 60/115 (52.2%) at week 96. While the protocol did not require CS-tapering upon entry to the OLM study, 12-week CS-free clinical remission was attained by 43/115 patients (37.4%) at week 48 and by 40/115 patients (34.8%) at week 96.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, among the patients that met clinical endpoints but not the corresponding CS-free clinical endpoints, many investigators chose not to attempt the optional CS-tapering.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fecal calprotectin
“The median FCP concentration decreased from 204.7 µg/g at baseline of OLM, to 86.6 µg/g at week 48 and 89.6 µg/g at week 96 (Table 2). Of the 167 patients with available data at week 48, 122/167 (73.1%) achieved FCP levels below 250 µg/g, and 109/167 (65.3%) achieved FCP levels below 150 µg/g. At week 96, 102 (69.4%) of the 147 patients with available data achieved FCP levels below 250 µg/g, and 91/147 (61.9%) achieved FCP levels below 150 µg/g.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miR-124 expression in blood and rectal tissue
Comparison with week 8 induction results
“Efficacy rates increased during the maintenance treatment period with obefazimod 50 mg relative to week 8 of the induction trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 48 of the OLM study, these percentages increased to 82% for clinical response and 61% for endoscopic improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
IBDQ planned as a secondary endpoint in the protocol
Missing IBDQ scores not imputed in the statistical analysis plan
Stool frequency and rectal bleeding recorded in a paper diary
Safety results
Treatment-emergent adverse events over 96 weeks
“At least 1 TEAE was reported for 148 (68.2%) of 217 obefazimod-treated patients (Table 3). The most common TEAEs reported in at least 5% of patients were COVID-19 (14.3%), headache (11.5%), UC (7.8%), nasopharyngitis (6.9%), back pain (5.5%), and arthralgia (5.1%). TESAEs were reported by 18 patients (8.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident). TEAEs leading to study discontinuation were reported in 17 patients (7.8%) (Table 4). These events included the worsening of disease (coded as colitis ulcerative and colitis), which resulted in the discontinuation of 9 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infections and infestations TESAEs, reported for 4 patients, comprised COVID-19/COVID-19 pneumonia (2 patients, 1.0%), urosepsis (1 patient, 0.5%), and appendicitis (1 patient, 0.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Laboratory results revealed no new or unexpected safety signals, and there were no clinically meaningful changes in laboratory parameters compared to week 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Headache after switching dose at entry
“Ten of the 25 patients who reported headache experienced them within the first 7 days after switching from placebo to obefazimod or from 25 to 50 mg upon entering the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Headache appears to be associated with the introduction to obefazimod treatment, as the rate was reduced to 11.5% of patients who received up to 96 weeks obefazimod 50 mg compared to 30.2% of patients who received obefazimod 50 mg during induction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse events leading to discontinuation
| Event | n (%) |
|---|---|
| Any TEAE | “17 (7.8)”View highlighted excerpt for this quote |
| Colitis ulcerative | “7 (3.2)”View highlighted excerpt for this quote |
| Colitis | “2 (0.9)”View highlighted excerpt for this quote |
| Ischemic stroke | “1 (0.5)”View highlighted excerpt for this quote |
| Left ventricular dysfunction | “1 (0.5)”View highlighted excerpt for this quote |
| Alanine aminotransferase increased | “1 (0.5)”View highlighted excerpt for this quote |
Adverse events in the posted results: participants affected / at risk (%)
| Event | ABX464 50 mg |
|---|---|
| All-cause mortality | “1/217 (0.46%)” |
| Serious adverse events, total | “18/217 (8.29%)” |
| Other adverse events, total | “148/217 (68.20%)” |
| COVID-19 | “31/217 (14.29%)” |
| Headache | “25/217 (11.52%)” |
| Colitis ulcerative | “17/217 (7.83%)” |
| Nasopharyngitis | “15/217 (6.91%)” |
Long-term safety: phase 2b open-label maintenance study through 96 weeks
“In total, 148/217 patients (68.2%) reported at least 1 treatment-emergent adverse event (TEAE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent TEAEs were COVID-19 (14.3%), headache (11.5%), UC (7.8%), and nasopharyngitis (6.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 1 malignant meningioma unrelated to treatment, and 1 death was reported, unrelated to treatment (car accident).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AESIs reported in more than 1 patient were headache, rash, and eczema, which were reported in 4 (1.8%), 3 (1.4%), and 2 patients (0.9%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No new safety risks emerged over 96 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
ABX464-104 was a single-group, open-label study without a control group, in which all 217 participants received obefazimod 50 mg once daily regardless of their induction treatment or response; the investigators state that “the results must be interpreted with caution due to the absence of a control group”. Entry into the second year required clinical response at week 48, and 6 participants did not continue because they did not achieve it or were unwilling. Efficacy was analyzed with nonresponder imputation, and the statistical analysis plan carried forward week 48 results for completers missing a week 96 assessment. Corticosteroid tapering was recommended and not mandatory; the protocol defined glucocorticoid-free clinical remission as no glucocorticoids for at least 8 weeks before week 48, and the published analysis used cessation for at least 12 weeks. Endpoint definitions differ between documents: the registry's week 48 outcome defines clinical response as a reduction in Mayo score of at least 3 points, while its week 48 continuation criterion and the publication use at least 2 points; the registry adds an at least 1-point decrease in stool frequency subscore to the clinical remission definition. At week 48, 177 of 217 participants had clinical response in the publication and the posted results, and the Form 20-F reports 178 (82%). The registry's detailed description states a 48-week treatment period and its arm description states 96 weeks. Echocardiography was added by amendment after enrollment was complete, without drug-free baseline measurements. Participants were enrolled at 69 centers in 14 countries in Europe and Canada, race and ethnicity were not collected, and 10 participants discontinued for “Other reason (e.g., Ukraine Crisis)”. The protocol planned IBDQ assessment at week 24 and week 48, and no IBDQ results were located in the publication or the posted results. Abivax personnel designed the trial with the principal academic investigators, and Abivax analyzed the data.
Limitations stated by the investigators
“Although the central evaluation of endoscopy data reduced the risk of bias in this open-label study, the results must be interpreted with caution due to the absence of a control group. Furthermore, steroid cycling was not accounted for in the NRI method, potentially limiting the interpretation of CS-free outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CS-free efficacy rates might have been higher had CS-tapering been required during the OLM study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Role of the funder
“Personnel from Abivax designed the trial in conjunction with the principal academic investigators. A contract research organization collected the trial data, Abivax analyzed the data, and all of the authors jointly interpreted the data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ABX464-101
Objective
Purpose stated in the ClinicalTrials.gov record
Proof-of-concept purpose described by the sponsor
Location and study date
Results posting date
Registered locations
Centers and countries reported by the sponsor
Centers and countries at the time of the extension study authorization
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “Double-blind, placebo-controlled, randomized study” |
| Masking description | “Double-Blind Treatment” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “32” |
Randomized, double-blind design and central endoscopy reading described by the sponsor
Induction phase of the phase 2 program
Eligibility criteria
Disease activity and background therapy in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms in the ClinicalTrials.gov record
Permitted background therapy at stable doses
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Clinical remission registered as the primary efficacy endpoint among secondary outcomes
Other registered secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size stated in the ABX464-102 protocol
Description of analysis sets
Analysis populations in the posted results
Statistical tests in the posted results
| Outcome | Method |
|---|---|
| Treatment-emergent adverse events | “Chi-squared” |
| Clinical remission | “Chi-squared” |
| Fecal calprotectin | “ANCOVA” |
| Total Mayo score | “ANCOVA” |
| Partial Mayo score | “ANCOVA” |
Results
Participant disposition
Participants completing per protocol, as reported by the sponsor
Roll-over into the ABX464-102 extension
Baseline characteristics
Baseline disease activity, disease duration, and prior advanced therapy
No evidence found.
Efficacy results
Clinical remission, clinical response, and endoscopic outcomes at week 8 reported by the sponsor
Week 8 results stated in the ABX464-102 protocol
Statistical comparisons of week 8 outcomes reported by the sponsor
Topline statistical comparisons and fecal calprotectin reported in 2018
Clinical remission at week 8 in the posted results, with arm titles as the record lists them
| Field | First arm listed | Second arm listed |
|---|---|---|
| Arm/group title | “ABX464 Matching Placebo Treatment Arm” | “ABX464 Treatment Arm” |
| Overall number of participants analyzed | “20” | “9” |
| Participants in clinical remission | “7” | “1” |
Mayo score change and fecal calprotectin at week 8 in the posted results
| Outcome | ABX464 (n=20) | Placebo (n=9) |
|---|---|---|
| Change from baseline in total Mayo score, mean (SD) | “-4.6(2.8)” | “-2.1(2.5)” |
| Change from baseline in partial Mayo score, mean (SD) | “-3.9(2.2)” | “-1.8(2.0)” |
| Participants with fecal calprotectin above 50 µg/g | “15” | “8” |
miR-124 expression in blood during ABX464-101 and ABX464-102
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Deaths, serious adverse events, and other adverse events in the posted results
| Measure, affected / at risk (%) | ABX464 | Placebo |
|---|---|---|
| All-cause mortality | “0/23 (0.00%)” | “0/9 (0.00%)” |
| Serious adverse events, total | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Nephrolithiasis left side (serious) | “0/23 (0.00%)” | “1/9 (11.11%)” |
| Other (not including serious) adverse events, total | “18/23 (78.26%)” | “5/9 (55.56%)” |
Other adverse events in at least two participants of either group
| Event, affected / at risk (%) | ABX464 | Placebo |
|---|---|---|
| Abdominal pain | “4/23 (17.39%)” | “1/9 (11.11%)” |
| Headache | “4/23 (17.39%)” | “0/9 (0.00%)” |
| Abdominal pain upper | “3/23 (13.04%)” | “0/9 (0.00%)” |
| Nausea | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Chest pain | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Influenza like illness | “2/23 (8.70%)” | “0/9 (0.00%)” |
| Hypophosphataemia | “1/23 (4.35%)” | “2/9 (22.22%)” |
Adverse event collection period
Study limitations
Summary
ABX464-101 was a randomized, double-blind, placebo-controlled phase 2a study in which 32 participants with moderately to severely active ulcerative colitis were randomized 2:1 to obefazimod 50 mg (23 participants) or placebo (9 participants) once daily for 8 weeks, at sites in six European countries. The registered primary endpoint was the number of participants with treatment-emergent adverse events; clinical remission by the total Mayo score at week 8 was registered as an outcome described as the “primary efficacy endpoint”. Efficacy was analyzed in participants without major protocol deviations who completed day 56 (20 receiving obefazimod and 9 receiving placebo), and the sponsor reported that 29 of the 32 participants “completed the study per protocol”. The planned sample size, stated in the ABX464-102 protocol, was a maximum of 30 participants, and no power calculation was located. Clinical remission at week 8 was reported as 35.0% with obefazimod and 11.1% with placebo, a difference the sponsor reported as not significant. The posted record lists the arm titles of the clinical remission outcome in the reverse order of the other outcomes, so its arm labels do not match its participant counts. The posted results analyze the change in partial and total Mayo scores by ANCOVA, whereas a 2019 press release reports p=0.029 for both, naming a likelihood ratio chi-square test for the partial Mayo score, and the 2018 topline release reports p<0.03 for the total Mayo score. Placebo clinical response is given as 33.0% in the ABX464-102 protocol and 33.3% in a 2021 press release. The sponsor describes the study drug as a tablet, and the posted record as a capsule. All 32 participants were White. Baseline disease activity, disease duration, and prior advanced therapy exposure were not reported in the readable sources, because the protocol and statistical analysis plan posted on ClinicalTrials.gov are image-only scans. No health-related quality of life results were located.
ABX464-102
Objective
Purpose stated in the ClinicalTrials.gov record
Primary, secondary, and echocardiography objectives in the protocol
Location and study date
Results posting date
Registered location
Sites, study period, and EudraCT number in the protocol
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “22” |
Open-label treatment for 48 months regardless of induction assignment
Data safety monitoring board and cardiovascular safety committee
Planned treatment duration of 12 months, January 2018, superseded in March 2019
Planned treatment duration of 24 months, March 2019, superseded in February 2022
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Enrollment based on willingness and investigator judgement
Enrollment of responders planned at authorization, January 2018
Treatment
Intervention in the ClinicalTrials.gov record
Allowed and prohibited concomitant medications
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Efficacy definitions in the statistical analysis plan
Changes from the protocol in the statistical analysis plan
Clinical response definition in the posted results
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Observed cases and non-responder imputation sets
Descriptive efficacy analysis planned in the protocol
Analysis populations in the posted results
Results
Participant disposition
Participants entering from the obefazimod and placebo induction groups
Participants remaining on treatment through year 2
Baseline characteristics
Demographics in the posted results
| Characteristic | ABX464 50 mg (N=22) |
|---|---|
| Age, years, mean (SD) | “42.4(14.3)” |
| Female | “9” |
| Male | “13” |
| White | “22” |
Clinical remission status at entry among participants remaining at month 12
Efficacy results
Month 48 outcomes with non-responder imputation in the posted results
| Outcome (N=22) | Quoted record |
|---|---|
| Participants with clinical response | “11” |
| Participants with clinical remission | “9” |
| Participants with endoscopic improvement | “9” |
| Participants with endoscopic remission | “6” |
| Change in total Mayo score, mean (SD) | “-3.0(3.4)” |
| Change in partial Mayo score, mean (SD) | “-2.2(2.4)” |
| Change in fecal calprotectin, µg/g, mean (SD) | “-299.69(472.28)” |
| Change in CRP, mg/L, mean (SD) | “2.29(4.82)” |
| Change in ESR, mm/hour, mean (SD) | “2.90(8.62)” |
Ulcerative colitis worsening reported as an adverse event (post hoc)
Month 12 interim results
Month 12 interim results stated in the protocol
Month 24 interim results with central endoscopy reading
Health-related quality of life and patient-reported outcomes
SF-36 component scores at up to 24 months in the posted results
| Outcome (N=22, non-responder imputation) | Change from day 0, mean (SD) |
|---|---|
| SF-36 physical component | “4.82(4.23)” |
| SF-36 mental component | “6.38(3.40)” |
SF-36 instrument and assessment schedule
Safety results
Adverse event counts in the posted results
Deaths and serious adverse events in the posted results
| Measure | Affected / at risk (%) |
|---|---|
| All-cause mortality | “0/22 (0.00%)” |
| Serious adverse events, total | “3/22 (13.64%)” |
| Myocardial infarction | “1/22 (4.55%)” |
| Enteropathic spondylitis | “1/22 (4.55%)” |
| Benign ovarian tumor | “1/22 (4.55%)” |
Investigator assessment of the serious adverse events
Other adverse events in at least 3 participants
| Event | Affected / at risk (%) |
|---|---|
| Other (not including serious) adverse events, total | “20/22 (90.91%)” |
| Colitis ulcerative | “7/22 (31.82%)” |
| Abdominal pain | “5/22 (22.73%)” |
| Nasopharyngitis | “5/22 (22.73%)” |
| Diarrhoea | “4/22 (18.18%)” |
| Vomiting | “3/22 (13.64%)” |
| Headache | “3/22 (13.64%)” |
Sponsor statements on safety at month 12 and year 2
Study limitations
Summary
ABX464-102 was a single-group, open-label extension without a control group, in which 22 participants who completed ABX464-101 (15 previously assigned to obefazimod and 7 to placebo) received obefazimod 50 mg once daily, at sites in Belgium, Hungary, and Poland (3, 9, and 10 participants). Enrollment was based on participant willingness and investigator judgement, and the protocol set no sample size beyond a “Maximum 30 subjects”. The planned treatment period was 12 months in a 2018 press release, 24 months after a data safety monitoring board recommendation reported in 2019, and 48 months in the 2022 protocol. The primary endpoint was the number of treatment-emergent adverse events; efficacy results were to be “presented descriptively”. Eleven of 22 participants completed the study. Interim efficacy was reported among participants with an endoscopy at each timepoint (12 of 16 in clinical remission at month 12, 11 of 16 at month 24, and 11 of 13 at month 36); endoscopies were read locally at month 12 and centrally at month 24. In the posted non-responder imputation analysis, 9 of 22 participants were in clinical remission at month 48. The statistical analysis plan defines clinical response by the modified Mayo score, and the posted outcome description defines it by the total Mayo score. Seven of 22 participants had ulcerative colitis worsening reported as an adverse event. SF-36 was assessed only to month 24, and the echocardiography endpoints were moved to a separate report that was not located. All 22 participants were White.
ABX464-108
Objective
Purpose stated in the ClinicalTrials.gov record
Objective of the three-year interim analysis
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Active, not recruiting” (opens the source at this quote in a new tab)
“Study Start (Actual) 2021-12-03” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2028-03” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2028-04” (opens the source at this quote in a new tab)
Registered locations
Data cutoff of the three-year interim analysis
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Open Label Follow-up Study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (estimated) | “203” |
Treatment period and follow-up in the ClinicalTrials.gov record
Dose de-escalation after the phase 2a and phase 2b open-label maintenance studies
Design described in the congress poster
Phase 2 program schema
“Obefazimod 50 mg (n=22)” (opens the source at this quote in a new tab)
“48 months ~4 years of treatment” (opens the source at this quote in a new tab)
“Obefazimod 50 mg (n=217)” (opens the source at this quote in a new tab)
“48 + 48 weeks ~2 years of treatment” (opens the source at this quote in a new tab)
“Up to 78 months” (opens the source at this quote in a new tab)
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Eligibility criteria shown in the congress presentation
Treatment
Intervention in the ClinicalTrials.gov record
Study outcomes
Rationale for using adverse events as the primary endpoint
Registered primary and secondary outcome measures
Statistical analysis description
Number of participants (Planned and analyzed)
Participants evaluated at the September 2024 data cutoff
Description of analysis sets
Intent-to-treat analysis with non-responder imputation
Non-responder imputation and as-observed analyses
Week 144 completer population and definition of prior advanced therapy inadequate response
Results
Participant disposition
Discontinuations and visit completion through week 144
Baseline characteristics
Clinical remission at study baseline
Characteristics at the start of the 25 mg dose among week 144 completers
| Characteristic | Week 144 completers (n=104) |
|---|---|
| Age, years, mean (SD) | “45.4 (12.74)” |
| Male, n (%) | “65 (62.5)” |
| UC duration, years, mean (SD) | “11.2 (7.02)” |
| Modified Mayo score 0 to 4, n (%) | “104 (100)” |
| C-reactive protein, mg/L, median | “2.2” |
| Fecal calprotectin, µg/g, median | “57.0” |
| Concomitant corticosteroids, n (%) | “6 (5.8)” |
| Concomitant 5-ASA, n (%) | “79 (76.0)” |
| Prior refractoriness to biologics, n (%) | “49 (47.1)” |
| Primary non-response, n (%) | “19 (38.8)” |
| Loss of response, n (%) | “30 (61.2)” |
Efficacy results
Clinical remission at weeks 48, 96, and 144 with non-responder imputation
Clinical and symptomatic remission in the non-responder imputation and as-observed analyses
Efficacy endpoints among week 144 completers by prior advanced therapy inadequate response
| Endpoint and subgroup | Baseline | Week 48 | Week 96 | Week 144 |
|---|---|---|---|---|
| Clinical remission, AT-IR naive (N=57) | “97%” | “91%” | “88%” | “90%” |
| Clinical remission, prior AT-IR (N=47) | “85%” | “77%” | “80%” | “79%” |
| Symptomatic remission, AT-IR naive (N=57) | “97%” | “97%” | “91%” | “95%” |
| Symptomatic remission, prior AT-IR (N=47) | “87%” | “83%” | “85%” | “85%” |
| Endoscopic improvement, AT-IR naive (N=57) | “100%” | “93%” | “95%” | “95%” |
| Endoscopic improvement, prior AT-IR (N=47) | “98%” | “92%” | “91%” | “89%” |
| Endoscopic remission, AT-IR naive (N=57) | “84%” | “77%” | “84%” | “81%” |
| Endoscopic remission, prior AT-IR (N=47) | “45%” | “53%” | “57%” | “62%” |
Fecal calprotectin through week 144
Two-year interim analysis among participants evaluated, September 2024 data cutoff
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events in all 130 participants
| Event | N (%) [IR/100 PY] |
|---|---|
| Any TEAE | “96 (73.8) [87.9]” |
| TEAE leading to discontinuation | “9 (6.9) [4.25]” |
| Serious TEAE | “8 (6.2) [3.86]” |
| Ulcerative colitis | “15 (11.5) [7.3]” |
| Nasopharyngitis | “11 (8.5) [5.4]” |
| Upper respiratory tract infection | “10 (7.7) [4.9]” |
| COVID-19 | “11 (8.5) [5.4]” |
| Hypertension | “7 (5.4) [3.4]” |
| Diarrhea | “5 (3.8) [2.4]” |
| Arthralgia | “5 (3.8) [2.4]” |
| Gastroenteritis | “4 (3.1) [1.9]” |
| Non-melanoma skin cancer | “1 (0.8) [0.5]” |
Deaths, opportunistic infections, and laboratory findings
Infections and malignancies across up to 7 years of treatment
Safety at the September 2024 data cutoff
Study limitations
Summary
ABX464-108 (Study 108) is an ongoing single-group, open-label extension without a control group, in which participants who completed the phase 2a (ABX464-102) or phase 2b (ABX464-104) open-label maintenance studies on obefazimod 50 mg, and who had a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0, received obefazimod 25 mg once daily. Entry selected participants already in endoscopic improvement after 2 to 4 years of treatment: of 174 who completed the earlier studies, 138 were eligible and 130 were treated, and 89% (116/130) were in clinical remission at study baseline. The study has no randomized comparison of 25 mg with continued 50 mg. Results come from an interim analysis presented at a congress and in a press release (January 5, 2026 cutoff; February 13, 2026 data transfer); no peer-reviewed report or registry results exist, and primary completion is estimated for March 2028. Clinical remission by non-responder imputation was 73%, 69%, and 68% at weeks 48, 96, and 144. The baseline characteristics and the subgroup analyses by prior advanced therapy inadequate response were reported only for the 104 participants who completed week 144, among whom clinical remission was 84% to 85% in the as-observed analysis. Sources state the treatment period differently: a maximum of 54 months in the registry summary, 78 months in the registry outcome time frame and the poster, and up to five additional years in the press release. The number completing week 48 is 113 in the poster and 114 on a presentation slide, and the number completing the phase 2a extension is 10 in the poster and 11 in the posted ABX464-102 results. The safety table excludes laboratory findings. No health-related quality of life results were located.
ABX464-906
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-906” |
| Location | “Locations France” |
| Start of trial | “Start of trial 13/06/2024” |
| End of trial | “End of trial 20/02/2025” |
Study design
Phase 1, two-part, open-label, single-sequence design
Drug-drug interaction trials described in the Form 20-F
Eligibility criteria
Participant type, age, and sex in the EU register
| Field | Register entry |
|---|---|
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |
| Population named in the title | “healthy male participants” |
Treatment
Single and multiple doses of obefazimod with rosuvastatin
Investigational medicinal product details not yet public
Study outcomes
Rationale for using rosuvastatin pharmacokinetics as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Enrollment in the two drug-drug interaction trials stated in the Form 20-F
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-906 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (13 June 2024 to 20 February 2025), one site in France, and 24 planned healthy volunteers aged 18 to 64 years; the 20-F reports two drug-drug interaction trials with 24 and 36 enrolled healthy volunteers. The objectives, endpoints, doses, and eligibility criteria are not public, and the summary of results is deferred under the rules for category 1 trials until 20 August 2027. The register limits the population to healthy men. No pharmacokinetic or safety result has been published.
Results publication deferred in the EU register
ABX464-910
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-910” |
| Location | “Locations Belgium” |
| Start of trial | “Start of trial 10/10/2023” |
| End of trial | “End of trial 31/08/2024” |
Study design
Phase 1 drug-drug interaction design
Drug-drug interaction trials described in the Form 20-F
Eligibility criteria
Participant type and age in the EU register
| Field | Register entry |
|---|---|
| Medical condition | “Medical condition(s) Healthy female participants of childbearing potential.” |
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |
Treatment
Multiple doses of obefazimod with ethinyl estradiol and drospirenone
Study outcomes
Rationale for using combined oral contraceptive pharmacokinetics as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Enrollment in the two drug-drug interaction trials stated in the Form 20-F
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-910 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (10 October 2023 to 31 August 2024), one site in Belgium, and 36 planned healthy women of childbearing potential aged 18 to 64 years. The doses, sampling schedule, endpoints, and the hormone measured are not public, and the summary of results is deferred until 28 February 2027. The 20-F states that the two drug-drug interaction trials were completed in 2025, whereas the register gives 31 August 2024 as the end of this trial. No pharmacokinetic or safety result has been published, so the effect of obefazimod on contraceptive exposure is unknown from public sources.
Results publication deferred in the EU register
ABX464-902
Objective
Primary and secondary objectives in the protocol
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start (actual) | “2020-12-17” |
| Primary completion (actual) | “2021-05-18” |
Results reporting dates in the registry record
| Field | Registry entry |
|---|---|
| Results first submitted | “2022-05-06” |
| Results first posted | “2026-11-09” |
| Other study ID numbers | “ABX464-902” |
Single site in Wales, United Kingdom
Study design
Phase 1, two-part, fixed-sequence, open-label crossover design
Perpetrator and victim roles in each part
Rationale for the open-label design
Eligibility criteria
Key inclusion and exclusion criteria in the registry record
Treatment
Dose selection and administration with food
Study outcomes
Rationale for using caffeine and Obefazimod cmax and AUC as the primary endpoints
Registered primary and secondary outcomes
In vitro basis for a CYP1A2 interaction study
Choice of caffeine and fluvoxamine as probe drugs
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation in the protocol
Participants screened, enrolled, and analyzed
Description of analysis sets
Safety and pharmacokinetic sets in the protocol
Planned statistical comparison
Results
Participant disposition
Baseline characteristics
Age and sex by study part
| Characteristic | Part A (24 participants) | Part B (35 participants) |
|---|---|---|
| Age, mean (standard deviation), years | “33.7(9.44)” | “36.8(9.75)” |
| Sex, participants | “Part A Number Analyzed 24 participants Female 5 Male 19” | “Part B Number Analyzed 35 participants Female 13 Male 22” |
Race and ethnicity not collected
Efficacy results
Part A: caffeine exposure with and without obefazimod (PK analysis set, 22 participants)
| Measure, mean (standard deviation) | Day 1, caffeine alone | Day 4, caffeine and ABX464 | Day 17, caffeine and ABX464 |
|---|---|---|---|
| Caffeine Cmax, ng/mL | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL | “7420(4760)” | “5460(2740)” | “1560(719)” |
Part B: obefazimod exposure with and without fluvoxamine (PK analysis set, 25 participants)
| Measure, mean (standard deviation) | Day 1, ABX464 alone | Day 11, ABX464 and fluvoxamine |
|---|---|---|
| ABX464 Cmax, ng/mL | “23.2(12.5)” | “33.4(19.0)” |
| ABX464 AUC, h*ng/mL | “55.2(25.7)” | “73.0(34.2)” |
Plain-language summary of the interaction results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Adverse events, serious adverse events, and deaths
| Measure | Part A overall | Part B overall |
|---|---|---|
| Participants with any other (nonserious) adverse event | “16/24 (66.67%)” | “30/35 (85.71%)” |
| Participants with a serious adverse event | “0/24 (0.00%)” | “0/35 (0.00%)” |
Most frequent adverse events by study part
| Adverse event | Part A overall | Part B overall |
|---|---|---|
| Headache | “13/24 (54.17%)” | “25/35 (71.43%)” |
| Nausea | “7/24 (29.17%)” | “20/35 (57.14%)” |
| Vomiting | “2/24 (8.33%)” | “11/35 (31.43%)” |
| Decreased appetite | “1/24 (4.17%)” | “15/35 (42.86%)” |
| Fatigue | “3/24 (12.50%)” | “14/35 (40.00%)” |
Study limitations
Summary
ABX464-902 enrolled 59 healthy adults in the United Kingdom (24 in Part A and 35 in Part B) and has no peer-reviewed publication. The registry results, first submitted in May 2022 and posted in November 2026, give means and standard deviations only. The protocol specified geometric least squares mean ratios with 90% confidence intervals, and neither the registry nor any other public source reports them. In Part A, the posted mean caffeine AUC was 7420 hng/mL on Day 1 alone and 1560 hng/mL on Day 17 after 14 days of obefazimod, and mean Cmax was 931 and 564 ng/mL; the HRA plain-language summary states that caffeine levels “remained similar in both the presence and absence of ABX464”, and the registry gives no analysis that reconciles the two. In Part B, mean obefazimod Cmax and AUC were higher with fluvoxamine (33.4 against 23.2 ng/mL and 73.0 against 55.2 h*ng/mL), and the HRA summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. Nine of 35 Part B participants were excluded from the pharmacokinetic analysis for vomiting and one for early withdrawal; the registry states that these exclusions “did not impact on the overall evaluation of the study objectives”. No metabolite (ABX464-N-glucuronide) result is posted, Part B used single 50 mg doses of obefazimod, and race and ethnicity were not collected.
Limitations and caveats stated in the registry results
ABX464-908
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-908” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/10/2023” |
| End of trial | “End of trial 11/09/2024” |
Study design
Phase 1 multiple-dose design with matched controls
Eligibility criteria
Participant type and age in the EU register
| Field | Register entry |
|---|---|
| Participants type | “Participants type Patients” |
| Age range | “Age range 65+ years, 18-64 years” |
Treatment
Multiple oral doses of obefazimod
Study outcomes
Rationale for using Obefazimod pharmacokinetics in hepatic impairment as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Enrollment stated in the Form 20-F
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-908 has only an EU register record and a sentence in the Form 20-F. The register gives the title, the dates (9 October 2023 to 11 September 2024), one site in Germany, and 32 planned participants; the 20-F reports 30 enrolled participants with mild or moderate hepatic impairment or matched normal liver function. The 20-F states that the trial was completed in 2025, whereas the register gives 11 September 2024 as its end. The classification method for hepatic impairment, the dose, the number per group, and the endpoints are not public, severe hepatic impairment was not studied, and the summary of results is deferred until 11 March 2027. The 20-F describes the results only as “supportive data” for the NDA, so no exposure ratio or safety result is available to inform dosing in hepatic impairment.
Results publication deferred in the EU register
ABX464-907
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-907” |
| Location | “Locations Germany” |
| Start of trial | “Start of trial 09/09/2024” |
| End of trial | “End of trial 14/10/2025” |
Study design
Additional Phase 1 trials described in the Form 20-F
Eligibility criteria
Participant type and age in the EU register
| Field | Register entry |
|---|---|
| Participants type | “Participants type Healthy volunteers, Patients” |
| Age range | “Age range 18-64 years, 65+ years” |
Treatment
Multiple oral doses of obefazimod
Study outcomes
Rationale for using Obefazimod pharmacokinetics in renal impairment as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-907 has only an EU register record. The register gives the title, the dates (9 September 2024 to 14 October 2025), one site in Germany, and 48 planned participants, who include patients and healthy volunteers aged 18 years or older. The Form 20-F does not name this trial among the completed Phase 1 trials. The categories of renal impairment, the dose, the number per group, the inclusion of participants on dialysis, and the endpoints are not public, and the summary of results is deferred until 14 April 2028. No exposure or safety result is available to inform dosing in renal impairment.
Results publication deferred in the EU register
ABX464-FE-001
Objective
Objectives stated in the publication
“The objectives of this study were to assess the relative bioavailability of single and repeated oral doses of 50 mg of ABX464 under fed or fasted conditions and to assess the clinical and biological tolerability of ABX464.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Purpose stated in the registry record
Location and study date
Single site in Mauritius, October 2014 to June 2015
“The study (protocol no. ABX464-FE-001) was approved by the Clinical Research Regulatory Council in Mauritius and conducted between October 2014 and June 2015 in accordance with the Declaration of Helsinki and good clinical practice guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“performed at a single site (CAP Research, Phoenix, Mauritius)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start | “2014-09” |
| Primary completion (actual) | “2015-06” |
| Other study ID numbers | “ABX464-FE-001” |
Study design
Open-label, randomized food-effect design in two groups
“This phase I study consisted of an open-label, food-effect, randomized study divided into 2 groups and performed at a single site (CAP Research, Phoenix, Mauritius).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the first group, a crossover design, 24 subjects received a single dose of 50 mg of ABX464 on 2 occasions (once under fasted conditions [treatment A] and once under fed conditions [treatment B]), separated by a washout period of at least 45 days. In the second group, a parallel design, 24 subjects received 50 mg of ABX464 every 3 days during 10 days under the fasted (treatment A) or fed (treatment B) condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second group involved the repeated-dose investigation with a conservative interval of 3-day dosing being chosen primarily because of safety considerations and also to assess whether this regimen was sufficient to maintain the metabolite at high levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy men aged 18 to 55 years
“Forty-eight healthy male subjects in good health on the basis of medical history, physical examination, vital signs, electrocardiogram (ECG), and routine laboratory safety tests, aged from 18 to 55 years, with BMIs of 17 to 28 kg/m2, and who were nonsmokers or light smokers (≤5 cigarettes per day) without history of frequent headache and/or migraine, recurrent nausea, and/or vomiting were included after having given their written informed consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Obefazimod 50 mg fasted or after a high-fat breakfast
“In group 1, a single oral dose of ABX464 (50 mg; two 25-mg capsules) was administered on the morning of day 0 of each period either after overnight fasting or after a high-fat breakfast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In group 2, ABX464 (50 mg) was administered on days 1, 4, 7, and 10 either after overnight fasting or after a high-fat breakfast.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using single-dose AUC and cmax under fed and fasted conditions as the primary endpoints
Registered primary and secondary outcomes
Reason for studying the food effect
“Food influence can be very important in the absorption of medicines, because food can lead to inefficiency in treatment or an increase in adverse events (AEs). It is important to investigate the food effect on the plasma levels of the drug in order to accordingly adapt doses for patients and optimize the treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Safety and pharmacokinetic populations
“All of the included subjects received the treatment as planned in the protocol and were analyzed in the safety analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was considered to have no impact on PK parameters, and thus all the subjects/periods were kept in the PK population except a subject in group 1 with no quantifiable ABX464 plasma concentrations after administration of ABX464 without food (treatment A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical comparison of fed and fasted conditions
“In 2 groups, for each parameter, a point estimate for the ratio of geometric means (GMs) (treatment B to treatment A) was obtained by calculating the difference of least-square means on the logarithmic scale and subsequent back-transformation with the exponential function.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Vomiting episodes and treatment received as planned
“Regarding the PK analysis set, 6 subjects (5 in group 1 and 1 in group 2) experienced vomiting episodes on day 1 more than 2 h after administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No AEs led to premature discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Age and body mass index by group
“Twenty-four male subjects aged from 20 to 53 years (mean, ∼35 years) and with a body mass index (BMI) of 17.4 to 28.2 kg/m2 were included in group 1, and 24 male subjects aged from 18 to 53 years (mean, ∼34 years) and with a BMI of 17.9 to 28.0 kg/m2 were included in group 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Single-dose obefazimod exposure, fed versus fasted (group 1)
| Parameter | Fasted, geometric mean | Fed, geometric mean | Point estimate (fed/fasted) | 90% CI |
|---|---|---|---|---|
| Cmax, ng/ml | “13.70”View highlighted excerpt for this quote | “43.71”View highlighted excerpt for this quote | “3.16”View highlighted excerpt for this quote | “2.45–4.07”View highlighted excerpt for this quote |
| AUC0–t, ng · h/ml | “34.52”View highlighted excerpt for this quote | “109.27”View highlighted excerpt for this quote | “3.12”View highlighted excerpt for this quote | “2.55–3.82”View highlighted excerpt for this quote |
Food increased obefazimod exposure and delayed absorption
“The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively). The apparent terminal elimination half-lives (t1/2s) under fed and fasted conditions were comparable, at about 0.80 h. The median time to maximum concentration (Tmax) was delayed from 1.5 to 2.8 h, and the ratio of the AUC0–∞ obtained under fed conditions to the AUC0–∞ obtained under fasted conditions (Frel) was 2.69.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Repeated dosing (group 2)
“Day 1 GM values for Cmax and AUC0–t were 42.92 ng/ml and 105.22 ng · h/ml under fed conditions compared to 10 ng/ml and 26.92 ng · h/ml, respectively, under fasted conditions, i.e., 329% and 291% higher.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With concomitant food intake, GM values of Cmax and AUC0–t were also substantially higher (415% and 294% higher, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Smaller food effect on the N-glucuronide metabolite
“The GM value of the Cmax of ABX464-NGlc given under fed conditions (2,401.52 ng/ml) was 7% lower than that when ABX464 was given under fasted conditions (2,572.81 ng/ml), while the GM AUC0–∞ was 6% lower.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The GM values for Cmax and t1/2 were approximately 190- and 120-fold higher, respectively, than those for the parent compound under fasted conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After the fourth administration, differences in ABX464-NGlc PK parameters under fasted and fed conditions were somewhat larger than those after the first, with GM values for the Cmax and AUC0–t being 35% and 33% higher, respectively, when ABX464 was given with food (Table 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Treatment-emergent adverse events
“A total of 50 treatment-emergent AEs (TEAEs) (27 under fasted conditions and 23 under fed conditions) were reported by 21 subjects out of 48 (data not shown). All of them were of mild to moderate intensity except for 1 case of severe abdominal injury not related to ABX464. The most frequent TEAEs consisted of headaches (29% of the subjects), nausea (12.5% of the subjects), and vomiting (12.5% of the subjects).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Concomitant food intake did not appear to reduce this side effect, as 4 subjects vomited under fed conditions and 2 under fasting conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was 1 serious AE (SAE) in each group resulting from an accident and an intercurrent disease (acute gastroenteritis 26 days after the last dosing). None of these could be reasonably related to ABX464.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No changes or clinically significant abnormalities in either laboratory parameters, vital signs, or ECG parameters were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
ABX464-FE-001 enrolled 48 healthy men in Mauritius in 2014 and 2015, 24 per group; the registry described 40 healthy Caucasian men. The repeated-dose group received 50 mg every 3 days, a schedule the authors chose for safety reasons, and compared fed and fasted conditions in a parallel design. The authors state that the study “does have a number of intrinsic limitations”: women were excluded, no age effects could be analyzed, and the terminal elimination rate constant after a single dose could be determined in only 17 participants fasted and 13 fed. One participant without quantifiable fasted concentrations was excluded from the pharmacokinetic analysis, and four authors are Abivax employees.
Limitations stated by the authors
“Also, as this study was the first to investigate food effect and repeated dosing, it does have a number of intrinsic limitations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, in order to eliminate any potential risk in the event of contraceptive failure, female subjects were not included in this study. The study is further limited in that no age effects could be analyzed, as the study was done with low subject numbers (n = 24 in each group), in the 18- to 55-year age group, as is standard for such early studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With treatment A (single treatment under fasted conditions), the terminal plasma elimination rate constant (kel) could be properly determined in only 17 subjects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With treatment B (single treatment under fed conditions), the kel could be properly determined in only 13 subjects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding and author affiliations
“This work was funded by Abivax, a publicly listed company (formerly known as Splicos).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“D.S., J.-M.S., P.G., and H.J.E. are Abivax employees and hold Abivax stock options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ABX464-001
Objective
Location and study date
Study dates and status in the registry record
| Field | Registry entry |
|---|---|
| Recruitment status | “Completed” |
| Study start | “2014-03” |
| Primary completion (actual) | “2014-07” |
| Other study ID numbers | “ABX464-001” |
Study design
Open-label, single ascending dose design with sentinel dosing
Eligibility criteria
Treatment
Single oral dose of 50 to 200 mg after overnight fasting
Study outcomes
Rationale for using the percentage of participants with at least one adverse event as the primary endpoint
Registered primary and secondary outcomes
Safety assessments and pharmacokinetic analytes
“Safety assessments consisted of vital signs, electrocardiogram, physical examination, laboratory tests and urinalysis. Pharmacokinetic parameters were calculated for ABX464 and its main metabolite ABX-464- N -glucuronide (ABX464-NGlc).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment in the registry record
| Field | Registry entry |
|---|---|
| Enrollment (actual) | “24” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Pharmacokinetics of obefazimod and its N-glucuronide metabolite
“ABX464's Cmax was observed approximately 2 h after administration in all groups. ABX464 was rapidly and substantially metabolized into ABX464-NGlc. The Cmax of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t1/2 (90-110 h). The ratio of metabolite to parent drug was consistent across the complete dose range.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
Tolerability across the 50 to 200 mg doses
Description of the first-in-human results in the food-effect publication
Study limitations
Summary
ABX464-001 gave a single oral dose of 50, 100, 150, or 200 mg after overnight fasting to 24 healthy men, 6 per dose group. It had no placebo group and no repeated dosing, enrolled men only, and all doses were given fasted. The full article is closed access, and the abstract gives no numerical pharmacokinetic parameters by dose, no adverse event counts, and no dose-proportionality analysis beyond stating that the metabolite-to-parent ratio “was consistent across the complete dose range”. The registry record posts no results, and four of eight authors list Abivax as their affiliation.
Author affiliations in the abstract record
“Scherrer D(1), Rouzier R(2), Noel Barrett P(3), Steens JM(1), Gineste P(1), Murphy RL(4), Tazi J(5), Ehrlich HJ(1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“(1)ABIVAX, 5 Rue de la Baume, 75008 Paris, France.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote